(Boursier.com) — Innate Pharma SA announces that the following abstracts, including an oral presentation, are selected for the 65th Annual Meeting of the ASH (American Society of Hematology) 2023, taking place from December 9 to 13, 2023 in San Diego (United States).
-Positive results from the Phase 2 TELLOMAK trial evaluating lacutamab in heavily pretreated patients with relapsed or refractory Sézary syndrome were selected for oral presentation
-Preliminary clinical data from the Phase 1b trial with lacutamab monotherapy and preclinical combinability data in patients with peripheral T-cell lymphoma will be presented in a poster
-Presented with SAR443579 / IPH6101, a potentially first-in-class NK Cell Engager engaging NKp46/CD16 receptors and targeting CD123. SAR443579/IPH6101, the most advanced drug candidate in the ANKET platform under development by our partner Sanofi, has demonstrated clinical remissions.
©2023 Boursier.com